29 January 2021
Novavax announced that its protein-based Covid-19 vaccine candidate NVX-CoV2373 has met its primary endpoint and achieved 89.3% efficacy in a Phase III clinical trial carried out in the UK. The company collaborated with the UK’s Vaccine Taskforce for the study. Novavax also published successful results from its Phase IIb study in South Africa.
RedHill Biopharma announced an agreement with Cosmo Pharmaceuticals to expand the manufacturing capacity for the former’s Covid-19 drug Opaganib to help address emerging viral strains following potential future global emergency use authorisations. The orally administered inhibitor achieve top results in its Phase II study, and is currently being evaluated in a Phase II/III trial.
Kintor Pharmaceutical announced that its clinical trial of Proxalutamide for treating hospitalised Covid-19 patients has been approved by the Institutional Review Board of Brazil. The trial has been approved for further accelerated review and the Brazilian government has agreed to provide medical resources to enable patient recruitment to begin at the weekend.
Speciality vaccine company Valneva has begun the production of its inactivated, adjuvanted Covid-19 vaccine candidate alongside its ongoing clinical studies. The company stated that it has begun production to optimise potential deliveries of the vaccine in the months ahead. Recruitment for a Phase I/II clinical study is now complete and will report initial results in April 2021.